Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: A randomized controlled trial
Background
Oxidative stress (OS), defined as an imbalance between excessive reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) production and antioxidant insufficiency, has been suggested to be involved in the pathogenesis of poor ovarian response (POR). Growth hormone (GH) can reduce OS in some cell types. This study investigated whether GH could improve OS in and in vitro fertilization and embryo transfer (IVF-ET) outcomes of poor ovarian responders.
Methods
This study enrolled 105 patients with POR and 58 patients without POR (controls) who were diagnosed according to the Bologna criteria and underwent conventional IVF-ET. Poor ovarian responders were randomly assigned to two groups: the POR-GH group, which received pretreatment with GH 4 IU/d on day 2 of the previous menstrual cycle before IVF until the trigger day , and the POR-C group, which received no pretreatment. The OS markers in follicular fluid (FF), ROS levels in granulosa cells (GCs), and IVF outcomes of the groups were compared.
Result(s)
The endometrial thickness on trigger day, number of cleaved embryos, number of higher quality embryos, and rates of implantation and clinical pregnancy were significantly increased in the POR-GH group compared with the POR-C group ( P < 0.05). Moreover, compared to those in the non-POR group, the FF malondialdehyde (MDA), total oxidant status (TOS), oxidative stress index (OSI) and ROS levels in GCs were significantly higher, whereas superoxide dismutase (SOD) and total antioxidant capacity (TAC) were significantly lower in the POR-C group (P < 0.05). Furthermore, compared with those in the POR-C group, the FF TAC was significantly increased in the POR-GH group, and the TOS, OSI and intracellular ROS levels were significantly reduced ( P < 0.05) .
Conclusion(s)
Pretreatment with GH alleviates OS and improves oocyte quality in and IVF outcomes of poor ovarian responders.
Clinical Trial Registration Number
ChiCTR1900021269 (Chinese Clinical Trial Registry).
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Posted 20 Aug, 2020
On 05 Sep, 2020
On 23 Aug, 2020
On 16 Aug, 2020
On 15 Aug, 2020
On 15 Aug, 2020
On 12 Aug, 2020
Received 03 Aug, 2020
On 29 Jul, 2020
Invitations sent on 26 Jul, 2020
On 08 Jul, 2020
On 07 Jul, 2020
On 07 Jul, 2020
On 21 Jun, 2020
Received 19 Jun, 2020
On 15 Jun, 2020
Invitations sent on 14 Jun, 2020
On 24 May, 2020
On 23 May, 2020
On 23 May, 2020
On 03 May, 2020
Received 21 Apr, 2020
On 16 Apr, 2020
Invitations sent on 06 Apr, 2020
On 13 Mar, 2020
On 12 Mar, 2020
On 12 Mar, 2020
On 12 Mar, 2020
Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: A randomized controlled trial
Posted 20 Aug, 2020
On 05 Sep, 2020
On 23 Aug, 2020
On 16 Aug, 2020
On 15 Aug, 2020
On 15 Aug, 2020
On 12 Aug, 2020
Received 03 Aug, 2020
On 29 Jul, 2020
Invitations sent on 26 Jul, 2020
On 08 Jul, 2020
On 07 Jul, 2020
On 07 Jul, 2020
On 21 Jun, 2020
Received 19 Jun, 2020
On 15 Jun, 2020
Invitations sent on 14 Jun, 2020
On 24 May, 2020
On 23 May, 2020
On 23 May, 2020
On 03 May, 2020
Received 21 Apr, 2020
On 16 Apr, 2020
Invitations sent on 06 Apr, 2020
On 13 Mar, 2020
On 12 Mar, 2020
On 12 Mar, 2020
On 12 Mar, 2020
Background
Oxidative stress (OS), defined as an imbalance between excessive reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) production and antioxidant insufficiency, has been suggested to be involved in the pathogenesis of poor ovarian response (POR). Growth hormone (GH) can reduce OS in some cell types. This study investigated whether GH could improve OS in and in vitro fertilization and embryo transfer (IVF-ET) outcomes of poor ovarian responders.
Methods
This study enrolled 105 patients with POR and 58 patients without POR (controls) who were diagnosed according to the Bologna criteria and underwent conventional IVF-ET. Poor ovarian responders were randomly assigned to two groups: the POR-GH group, which received pretreatment with GH 4 IU/d on day 2 of the previous menstrual cycle before IVF until the trigger day , and the POR-C group, which received no pretreatment. The OS markers in follicular fluid (FF), ROS levels in granulosa cells (GCs), and IVF outcomes of the groups were compared.
Result(s)
The endometrial thickness on trigger day, number of cleaved embryos, number of higher quality embryos, and rates of implantation and clinical pregnancy were significantly increased in the POR-GH group compared with the POR-C group ( P < 0.05). Moreover, compared to those in the non-POR group, the FF malondialdehyde (MDA), total oxidant status (TOS), oxidative stress index (OSI) and ROS levels in GCs were significantly higher, whereas superoxide dismutase (SOD) and total antioxidant capacity (TAC) were significantly lower in the POR-C group (P < 0.05). Furthermore, compared with those in the POR-C group, the FF TAC was significantly increased in the POR-GH group, and the TOS, OSI and intracellular ROS levels were significantly reduced ( P < 0.05) .
Conclusion(s)
Pretreatment with GH alleviates OS and improves oocyte quality in and IVF outcomes of poor ovarian responders.
Clinical Trial Registration Number
ChiCTR1900021269 (Chinese Clinical Trial Registry).
Figure 1
Figure 2